FDA accepted PD-L1 inhibitor durvalumab for the treatment of endometrial cancer
On June 14, 2024, the U.S. FDA approved AstraZeneca’s Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch …
On June 14, 2024, the U.S. FDA approved AstraZeneca’s Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch …
